Predict your next investment

Venture Capital
anthemcapital.com

See what CB Insights has to offer

Investments

53

Portfolio Exits

13

Funds

2

About Anthem Capital

Anthem Capital Management is an early stage venture capital firm that invests exclusively in the Mid-Atlantic states. Anthem seeks opportunities in IT / telecom and healthcare / life sciences industries. IT investments are most frequently made in enterprise software or network management software companies. Medical investments tend to fall into three categories: medical devices, biotechnology or healthcare. Anthem invests in early to expansion stage opportunities. Typically, an initial investment is made in the Series A or Series B institutional venture capital round and ranges from $1 million to $2 million. It seeks to invest between $2 million and $5 million in a company from the first private equity round through exit.

Anthem Capital Headquarter Location

1448 South Rolling Road Suite 200

Baltimore, Maryland, 21227,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Anthem Capital News

Medical Device Specialist Senseonics Raises $20 Million in Funding

Jun 9, 2014

Current investors Anthem Capital, Greenspring Associates, Healthcare Ventures  and other strategic partners participated in the financing round. Senseonics, a medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, announced that it has raised an additional $20 million of private equity financing.Current investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, New Enterprise Associates and other strategic partners all participated in the financing round.Senseonics, (formerly known as Sensors for Medicine and Science, is developing an implantable continuous glucose sensor designed for highly accurate, long-term wear. The Continuous Glucose Monitoring System (CGMS) includes a miniaturized sensor, transmitter and mobile medical application.Based on fluorescence sensing technology, the sensor is designed to be inserted into the subcutaneous space of the upper arm and communicate with the transmitter to wirelessly transmit glucose levels to a smartphone. After insertion, the sensor functions automatically and continuously, and the system is intended to enable people with diabetes to more confidently live their lives with more ease. Senseonics has recently begun its European pivotal trials and expect to complete site initiation of all seven European sites before the end of summer, according to the company. "We’re very happy of the continued support from our investors as we near the completion of the product development efforts for our first generation long-term CGM system," Tim Goodnow, CEO and president of Senseonics, said in a statement.Continuous glucose monitoring has the potential to further help diabetes patients examine how their glucose level reacts to insulin, exercise, food, and other factors. Recent studies have shown that CGM is effective at improving glucose control while minimizing severe hypoglycemia. In addition, accurate continuous glucose monitors are a key component of the promising artificial pancreas ongoing studies that could potentially offer additional freedom in the management of diabetes.Senseonics also announced that Mirasol Panlilio, formerly of Abbott Diabetes Care and LifeScan, has joined the company as vice president of global sales and marketing. "We are excited that Mirasol has agreed to join Senseonics. She brings a wealth of first-hand experience and creative energy in delivering novel diabetes devices to market," Goodnow continued. "Having Mirasol join us at this time shows our focus will begin to shift towards commercialization. "Last year the company was granted ISO 13485:2003 certification of its quality management system, which represents the requirements for comprehensive quality management system for design and manufacture of medical devices.The scope of certification includes the design, development, manufacturing, servicing and distribution of active implantable glucose sensors and accessories for continuous glucose monitoring.The European Union, Canada and Australia recognize ISO 13485 certification as a means of meeting regulatory requirements for conformity assessment, and U.S. FDA’s Quality System Regulations (21CFR820) is harmonized with ISO 13485.  

Anthem Capital Investments

53 Investments

Anthem Capital has made 53 investments. Their latest investment was in Triumfant as part of their Series C on July 7, 2014.

CBI Logo

Anthem Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/24/2014

Series C

Triumfant

$2.5M

No

2

6/26/2014

Debt

Triumfant

$7.35M

No

4

6/5/2014

Series E

Senseonics

$20M

No

2

11/1/2011

Series D

Subscribe to see more

$99M

Subscribe to see more

0

10/7/2009

Series C

Subscribe to see more

$99M

Subscribe to see more

0

Date

7/24/2014

6/26/2014

6/5/2014

11/1/2011

10/7/2009

Round

Series C

Debt

Series E

Series D

Series C

Company

Triumfant

Triumfant

Senseonics

Subscribe to see more

Subscribe to see more

Amount

$2.5M

$7.35M

$20M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

2

0

0

Anthem Capital Portfolio Exits

13 Portfolio Exits

Anthem Capital has 13 portfolio exits. Their latest portfolio exit was Triumfant on October 20, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/20/2016

Acquired

$99M

1

3/18/2016

IPO

$99M

Public

1

1/10/2014

IPO

$99M

Public

1

10/28/2010

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/17/2010

Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/20/2016

3/18/2016

1/10/2014

10/28/2010

6/17/2010

Exit

Acquired

IPO

IPO

Acquired

Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Anthem Capital Fund History

2 Fund Histories

Anthem Capital has 2 funds, including Anthem Capital II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2004

Anthem Capital II LP

Early-Stage Venture Capital

Closed

$75M

1

12/31/1994

Anthem Capital LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2004

12/31/1994

Fund

Anthem Capital II LP

Anthem Capital LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$75M

$99M

Sources

1

10

Anthem Capital Team

7 Team Members

Anthem Capital has 7 team members, including current General Partner, William Gust.

Name

Work History

Title

Status

William Gust

General Partner

Current

Xander Perry

General Partner

Current

Gerry Schaafsma

General Partner

Current

Ed Spiva

General Partner

Current

Martin Carsky

Great Panther Mining, Cryopak, and Burntsand

Executive Vice President

Former

Name

William Gust

Xander Perry

Gerry Schaafsma

Ed Spiva

Martin Carsky

Work History

Great Panther Mining, Cryopak, and Burntsand

Title

General Partner

General Partner

General Partner

General Partner

Executive Vice President

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.